N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients:: Prognostic value of baseline and follow-up measurements

被引:35
作者
Gutierrez, Orlando M. [1 ]
Tamez, Hector [1 ]
Bhan, Ishir [1 ]
Zazra, James [2 ]
Tonelli, Marcello [3 ]
Wolf, Myles [1 ]
Januzzi, James L. [1 ]
Chang, Yuchiao [1 ]
Thadhani, Ravi [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA
[2] Spectra Labs, Rockleigh, NJ USA
[3] Univ Alberta, Dept Med, Edmonton, AB, Canada
关键词
D O I
10.1373/clinchem.2007.101691
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associated with increased cardiovascular mortality in chronic hemodialysis patients. Previous studies focused on prevalent dialysis patients and examined single measurements of NT-proBNP in time. METHODS: We measured NT-proBNP concentrations in 2990 incident hemodialysis patients to examine the risk of 90-day and 1-year mortality associated with baseline NT-proBNP concentrations. In addition, we calculated the change in concentrations after 3 months in a subset of 585 patients to examine the association between longitudinal changes in NT-proBNP and subsequent mortality. RESULTS: Increasing quartiles of NT-proBNP were associated with a monotonic increase in 90-day [quartile 1, referent; from quartile 2 to quartile 4, hazard ratio (HR) 1. 7- 6.3, P < 0.001] and 1-year (quartile 1, referent; from quartile 2 to quartile 4, HR 1.7-4.9, P < 0.001) all-cause mortality. After multivariable adjustment, these associations remained robust. When examined using a multivariable fractional polynomial, increased NT-proBNP concentrations were associated with increased 90-day (HR per unit increase in log NT-proBNP 1.5, 95% Cl 1.3-1.7) and 1-year (HR per unit increase in log NT-proBNP 1.4, 95% Cl 1.3-1.5) all-cause mortality. In addition, patients with the greatest increase in NT-proBNP after 3 months of dialysis had a 2.4-fold higher risk of mortality than those with the greatest decrease in NT-proBNP. CONCLUSIONS: NT-proBNP concentrations are independently associated with mortality in incident hemodialysis patients. Furthermore, the observation that longitudinal changes in NT-proBNP concentrations were associated with subsequent mortality suggests that monitoring serial NT-proBNP concentrations may represent a novel tool for assessing adequacy and guiding therapy in patients initiating hemodialysis. (C) 2008 American Association for Clinical Chemistry.
引用
收藏
页码:1339 / 1348
页数:10
相关论文
共 40 条
[1]   Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) [J].
Anand, IS ;
Fisher, LD ;
Chiang, YT ;
Latini, R ;
Masson, S ;
Maggioni, AP ;
Glazer, RD ;
Tognoni, G ;
Cohn, JN .
CIRCULATION, 2003, 107 (09) :1278-1283
[2]  
[Anonymous], AM J KIDNEY DIS S3
[3]   Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement - Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study [J].
Anwaruddin, S ;
Lloyd-Jones, DM ;
Baggish, A ;
Chen, A ;
Krauser, D ;
Tung, R ;
Chae, C ;
Januzzi, JL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (01) :91-97
[4]   Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death [J].
Apple, FS ;
Murakami, MM ;
Pearce, LA ;
Herzog, CA .
CLINICAL CHEMISTRY, 2004, 50 (12) :2279-2285
[5]   Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease [J].
Apple, FS ;
Murakami, MM ;
Pearce, LA ;
Herzog, CA .
CIRCULATION, 2002, 106 (23) :2941-2945
[6]   Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists [J].
Azizi, M ;
Ménard, J .
CIRCULATION, 2004, 109 (21) :2492-2499
[7]   Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease [J].
Berger, Alan K. ;
Duval, Sue ;
Manske, Connie ;
Vazquez, Gabriela ;
Barber, Cheryl ;
Miller, Leslie ;
Luepker, Russell V. .
AMERICAN HEART JOURNAL, 2007, 153 (06) :1064-1073
[8]   Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure [J].
Bettencourt, P ;
Frioes, F ;
Azevedo, A ;
Dias, P ;
Pimenta, J ;
Rocha-Gonçalves, F ;
Ferreira, A .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 93 (01) :45-48
[9]   Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure [J].
Chan, Anna K. Y. ;
Sanderson, John E. ;
Wang, Tian ;
Lam, Wynnie ;
Yip, Gabriel ;
Wang, Mei ;
Lam, Yat-Yin ;
Zhang, Yan ;
Yeung, Leata ;
Wu, Eugene B. ;
Chan, Wilson W. M. ;
Wong, John T. H. ;
So, Nina ;
Yu, Cheuk-Man .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :591-596
[10]   Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction - The Reversal of ventricular remodeling with Toprol-XL (REVERT) trial [J].
Colucci, Wilson S. ;
Kolias, Theodore J. ;
Adams, Kirkwood F. ;
Armstrong, William F. ;
Ghali, Jalal K. ;
Gottlieb, Stephen S. ;
Greenberg, Barry ;
Klibaner, Michael I. ;
Kukin, Marrick L. ;
Sugg, Jennifer E. .
CIRCULATION, 2007, 116 (01) :49-56